GoldenGolden
Advanced Search
Coherus BioSciences

Coherus BioSciences

A biotechnology company in California that focuses on developing, manufacturing and commercializing biologic therapeutics or biosimilars for oncology and inflammatory diseases.

Coherus Biosciences is a biotechnology company in California that focuses on developing, manufacturing and commercializing biologic therapeutics or biosimilars for oncology and inflammatory diseases. Founded 2010 in Redwood City, California, United States by Stephen C. Glover, the company focuses on process science, analytical characterization, protein production, and clinical-regulatory development of biosimilars. Biosimilars are safe, effective, and affordable alternatives to existing brand biologics that meet the same standards set by the US Food and Drug Administration (FDA). They have lower costs and are believed to decrease the burdens of hospitalization and ambulatory care. Coherus Biosciences develops biologic medicines such as immunology therapies, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates, ophthalmology biosimilar candidates, and oncology biosimilar candidates.

Geographically, the group has a business presence in the United States and other countries.  The company has a strategic collaboration with Daiichi Sankyo.

Timeline

May 2014
Coherus BioSciences raises a $55,000,000 series C round from F-Prime Capital Partners, KKR, Lilly Ventures, RA Capital Management, Rock Springs Capital, Venrock and Vivo Capital.
2010
Founded

Funding rounds

People

Name
Role
LinkedIn

Dennis Lanfear

President, Chief Executive Officer & Chairman

Thomas Fitzpatrick JD

Chief Legal Officer

Vladimir Vexler

Chief Scientific Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 29, 2021
BioSpace
Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.